• Prana Biotechnology Ltd., of Parkville, Australia, said it completed its Phase II Reach2HD trial testing PBT2 in patients with early to midstage Huntington's disease. Results from the 109-patient study are expected in October. The primary outcome is safety and tolerability, with secondary outcomes including measures from the cognitive, motor and behavioral domains affected in Huntington's disease.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST